Novel Modulators of Melanocortin Receptors for the Treatment of Depression and Anxiety
Title: Novel Modulators of Melanocortin Receptors for the Treatment of Depression and Anxiety Invention: The invention is the use of the melanocortin 5 receptor (MC5R) ligand to treat depressive and anxiety disorders. MC5R antagonism is the proposed mechanism of action. Background: Depression and anxiety often have similar treatment, but experiencing the full effects of current pharmacotherapy can range from weeks to months. Antidepressants and anxiolytics are associated with a number of side effects including an increased risk of suicidal thoughts in those taking antidepressants. Therefore, a novel pathway is needed for rapid onset with minimal side effects. Applications:Pharmaceutical companies Advantages:Provides a treatment for depressive and anxiety disorders Licensing Manager:Paul EynottPaulE@tla.arizona.edu(520) 471-3612
美国
